Therapeutic effects of erythropoietin in murine models of endotoxin shock

Critical Care Medicine

Volumn 37, Issue 3, 2009, Pages 889-898

  Aoshiba, Kazutetsu ^a   Onizawa, Shigemitsu ^a   Tsuji, Takao ^a   Nagai, Atsushi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Erythropoietin; Hypoxia; Mouse; Nitric oxide; Septic shock

Indexed keywords

CASPASE 3; CASPASE 7; CYTOKINE; DNA NUCLEOTIDYLEXOTRANSFERASE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; PEROXYNITRITE; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA; ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CECUM; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE PERFORATION; LIVER; LUNG; MALE; MORTALITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; SEPTIC SHOCK; SMALL INTESTINE; SPLEEN; SURVIVAL TIME; THYMUS; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL;

ANIMALS; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; MALE; MICE; MICE, INBRED BALB C; SHOCK, SEPTIC;

EID: 62849112815     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819b8371     Document Type: Article

References (52)

1. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
2. Annane D, Bellissant E, Cavaillon J-M: Septic shock. Lancet 2005; 365:63-78
3. Remick DG: Pathophysiology of sepsis. Am J Pathol 2007; 170:1435-1444
4. Riedemann NC, Guo R-F, Ward PA: Novel strategies for the treatment of sepsis. Nat Med 2003; 9:517-524
5. Sprung CL, Annane D, Keh D, et al: Hydro-cortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124
6. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327
7. Jelkmann W: Erythropoietin: Structure, control of production, and function. Physiol Rev 1992; 72:449-489
8. Digicaylioglu M, Bichet S, Marti HH, et al: Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 1995; 92:3717-3720
9. Westenfelder C, Biddle DL, Baranowski RL: Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55:808-820
10. Foster DL, Moe OL, Hsia CC: Upregulation of erythropoietin receptor during postnatal and postpneumonectomy lung growth. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1107-L1115
11. Farrell F, Lee A: The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologists 2004; 9:18-30
12. Maiese K, Li F, Chong ZZ: Erythropoietin in the brain: Can the promise to protect be fulfilled? Trends Pharmacol Sci 2004; 25: 577-583
13. Sharples EJ, Yaqoob MM: Erythropoietin in experimental acute renal failure. Nephron Exp Nephrol 2006; 104:e83-e84
14. Abdelrahman M, Sharples EJ, McDonald MC, et al: Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004; 22: 63-69
15. Wu H, Ren B, Zhu J, et al: Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur J Cardiothorac Surg 2006; 29:902-907
16. Squadrito F, Altavilla D, Squadrito G, et al: Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. Br J Phamacol 1999; 127:482-488
17. Akimoto T, Kusano E, Muto S, et al: The effect of erythropoietin on interleukin-1β mediated increase in nitric oxide synthesis in vascular smooth muscle cells. J Hypertens 1999; 17:1249-1256
18. Genc K, Genc S, Baskin H, et al: Erythropoietin decreases cytotoxicity and nitric oxide formation induced by inflammatory stimuli in rat oligodendrocytes. Physiol Res 2006; 55:33-38
19. Chandra A, Enkhbaatar P, Nakano Y, et al: Sepsis: Emerging role of nitric oxide and selectins. Clinics 2006; 61:71-76
20. Ghezzl P, Brines M: Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 2003; 11:S37-S44
21. Savino R, Ciliberto G: A paradigm shift for erythropoietin: No longer a specialized growth factor, but rather an all-purpose tissue-protective agent. Cell Death Differ 2004; 11: S2-S4
22. Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. Lancet 2005; 293:90-95
23. Corwin HL, Gettinger A, Pearl RG, et al: Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 2002; 288:2827-2835
24. Wand H, Liao H, Ochani M, et al: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10:1216-1221
25. Yang H, Ochani M, Li J, et al: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101:296-301
26. Pearce ML, Yamashita K, Beazell J: Measurement of pulmonary edema. Circ Res 1965; 16:482-488
27. Leers MP, Kolgen W, Bjoklund V, et al: Im-munocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999; 5:562-572
28. Kamolz LP, Giovanali P, Haslik W, et al: Continuous free-flap monitoring with tissue-oxygen measurements: Three-year experience. J Reconstr Microsurg 2002; 18: 487-491
29. Blouw B, Song H, Tihan T, et al: The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003; 4:133-146
30. Yasuda H, Yuen PST, Hu X, et al: Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int 2006; 69:1535-1542
31. Brown KA, Brain SD, Pearson JD, et al: Neutrophils in development of multiple organ failure in sepsis. Lancet 2006; 368:154-169
32. Weshche-Soldato DE, Swan RZ, Chung CS, et al: The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 2007; 8:493-500
33. Coopersmith CM, Stromberg PE, Dunne WM, et al: Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. JAMA 2002; 287: 1716-1721
34. Hotchkiss RS, Chang KC, Swanson PE, et al: Caspase inhibitors improve survival in sepsis: A critical role of the lymphocyte. Nat Immunol 2000; 1:496-501
35. Hotchkiss RS, Tinsley KW, Karl IE: Role of apoptotic cell death in sepsis. Scand J Infect Dis 2003; 35:585-592
36. Koroglu TF, Yilmaz O, Ozer E, et al: Erythropoietin attenuates lipopolysaccharide-induced splenic and thymic apoptosis in rats. Physiol Res 2006; 55:309-316
37. Yang CW, Li C, Jung JY, et al: Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003; 17:1754-1765
38. Lehner MD, Marx D, Boer R, et al: In vivo characterization of the novel imidazopyri-dine BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5- b]pyridine], a potent and highly selective inhibitor of inducible nitric-oxide synthase. J Pharmacol Exp Ther 2006; 317:181-187
39. Metejovic M, Krouzecky A, Martinkova V, et al: Selective inducible nitric oxide synthase inhibition during long-term hyperdynamic porcine bacteremia. Shock 2004; 21:458-465
40. Okamoto I, Abe M, Shibata K, et al: Evaluating the role of inducible nitric oxide synthase using a novel and selective inducible nitric oxide syn-thase inhibitor in septic lung injury produced by cecal ligation and puncture. Am J Respir Crit Care Med 2000; 162:716-722
41. Strunk V, Hahnenkamp K, Schneuing M, et al: Selective iNOS inhibition prevents hypotension in septic rats while preserving endo-thelium-dependent vasodilatation. Anesth Analg 2001; 92:681-687
42. Cauweis A: Nitric oxide in shock. Kidney Int 2007; 72:557-565
43. d'Uscio LV, Smith LA, Santhanam AV, et al: Essential role of endothelial nitric oxide syn-thase in vascular effects of erythropoietin. Hypertension 2007; 49:1142-1148
44. Wang XO, Vazini ND: Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999; 33:894-899
45. Wang W, Mitra A, Poole B, et al: Endothelial nitric oxide synthase-deficient mice exhibit increased susceptibility to endotoxin-in-duced acute renal failure. Am J Physiol Renal Physiol 2004; 287:F1044-F1048
46. Connelly L, Madhani M, Hobbs AJ: Resistance to endotoxic shock in endothelial nitric-oxide synthase (eNOS) knock-out mice: A pro-inflammatory role for eNOS-derived NO in vivo. J Biol Chem 2005; 280: 10040-10046
47. McGown CC, Brookes ZL: Beneficial effects of statins on the microcirculation during sepsis: The role of nitric oxide. Br J Anaesth 2007; 98:163-175
48. Cuzzocrea S, Di Paola R, Mazzon E, et al: Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 2006; 34:1168-1177
49. Ehrenreich H, Hasselblatt M, Dembowski C, et al: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8:495-505
50. Leist M, Ghezzi P, Grasso G, et al: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305:239 -242
51. Silver M, Corwin MJ, Bazan A, et al: Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: A randomized, double-blind, placebo-controlled trial. Crit Care Med 2006; 34:2310-2316
52. Corwin HL, Gettinger A, Fabian TC, et al: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357:965-976